ARTICLE | Clinical News
Phase III results for Actelion's Veletri
March 20, 2001 8:00 AM UTC
Actelion (SWX:ATLN) and partner Genentech (DNA) said that in a placebo-controlled Phase III trial, its Veletri tezosentan significantly improved the cardiac index in 292 patients with acute heart fail...